The Selective Cytopheretic Device: A Novel Cell-directed Extracorporeal Therapy Targeting the Host-Response

Time: 9:30 am
day: Conference Day 2


  • Despite improvements in critical care medicine, acute kidney injury continues to cause high mortality rates in critically ill patients.
  • AKI promotes a systemic inflammatory response resulting in microvascular damage and can lead to multi-organ dysfunction.
  • This session will describe the processes of a dysregulated immune response, the mechanism of action of the novel selective cytopheretic device, FDA approval in pediatric AKI due to sepsis, and the study design of the pivotal NEUTRALIZE-AKI trial in adult AKI